Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Mar 10, 2014	Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results SAN DIEGO , March 10, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014 , after	View HTML Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results 12.4 KB
Toggle Summary Mar 25, 2014	Evoke Pharma Reports Fourth Quarter and Year End 2013 Results SOLANA BEACH, Calif. , March 25, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013 .	View HTML Evoke Pharma Reports Fourth Quarter and Year End 2013 Results 28.1 KB
Toggle Summary Apr 22, 2014	Evoke Pharma Initiates Phase 3 Clinical Trial of EVK-001 for Treatment of Gastroparesis First Patient Enrolled in Study of Novel Intranasal Formulation and Delivery of Metoclopramide	View HTML Evoke Pharma Initiates Phase 3 Clinical Trial of EVK-001 for Treatment of Gastroparesis 16.8 KB
Toggle Summary Apr 28, 2014	Evoke Pharma Announces That EVK-001 Phase 2b Results Will be Presented at Digestive Disease Week 2014 SOLANA BEACH, Calif. , April 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from the Company's Phase 2b clinical trial of EVK-001, a novel intranasal formulation	View HTML Evoke Pharma Announces That EVK-001 Phase 2b Results Will be Presented at Digestive Disease Week 2014 16.3 KB
Toggle Summary May 06, 2014	Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2014 Financial Results SOLANA BEACH, Calif. , May 6, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the First Quarter of 2014 on Tuesday, May 13, 2014 ,	View HTML Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2014 Financial Results 12.3 KB
Toggle Summary May 13, 2014	Evoke Pharma Reports First Quarter 2014 Results SOLANA BEACH, Calif. , May 13, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2014 .	View HTML Evoke Pharma Reports First Quarter 2014 Results 25.8 KB
Toggle Summary May 28, 2014	Evoke Pharma Secures $4.5 Million Loan Facility With Square 1 Bank SOLANA BEACH, Calif. , May 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has secured a $4.5 million term loan agreement with Square 1 Bank (Nasdaq:SQBK).	View HTML Evoke Pharma Secures $4.5 Million Loan Facility With Square 1 Bank 17.4 KB
Toggle Summary Jul 30, 2014	Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results SOLANA BEACH, Calif. , July 30, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2014 on Wednesday, August 13,	View HTML Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results 12.3 KB
Toggle Summary Aug 12, 2014	Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001 SOLANA BEACH, Calif. , Aug. 12, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001,	View HTML Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001 14.9 KB
Toggle Summary Aug 13, 2014	Evoke Pharma Reports Second Quarter 2014 Results SOLANA BEACH, Calif. , Aug. 13, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2014 .	View HTML Evoke Pharma Reports Second Quarter 2014 Results 27.5 KB